Faron Pharmaceuticals Oy (FARN) - Net Assets
Based on the latest financial reports, Faron Pharmaceuticals Oy (FARN) has net assets worth GBX-16.25 Million GBX (≈ $-1.98K USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX16.20 Million ≈ $1.97K USD) and total liabilities (GBX32.45 Million ≈ $3.95K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check FARN cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX-16.25 Million |
| % of Total Assets | -100.26% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -187.33% |
| Growth Volatility | 247.89 |
Faron Pharmaceuticals Oy - Net Assets Trend (2012–2024)
This chart illustrates how Faron Pharmaceuticals Oy's net assets have evolved over time, based on quarterly financial data. Also explore FARN total asset value for the complete picture of this company's asset base.
Annual Net Assets for Faron Pharmaceuticals Oy (2012–2024)
The table below shows the annual net assets of Faron Pharmaceuticals Oy from 2012 to 2024. For live valuation and market cap data, see Faron Pharmaceuticals Oy market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | GBX-9.76 Million ≈ $-1.19K |
+35.61% |
| 2023-12-31 | GBX-15.16 Million ≈ $-1.84K |
-32.11% |
| 2022-12-31 | GBX-11.48 Million ≈ $-1.40K |
-493.28% |
| 2021-12-31 | GBX2.92 Million ≈ $355.04 |
+257.82% |
| 2020-12-31 | GBX-1.85 Million ≈ $-224.97 |
-214.84% |
| 2019-12-31 | GBX1.61 Million ≈ $195.89 |
+336.31% |
| 2018-12-31 | GBX369.00K ≈ $44.90 |
-92.22% |
| 2017-12-31 | GBX4.74 Million ≈ $577.09 |
-56.42% |
| 2016-12-31 | GBX10.88 Million ≈ $1.32K |
-2.64% |
| 2015-12-31 | GBX11.18 Million ≈ $1.36K |
+1040.91% |
| 2014-12-31 | GBX-1.19 Million ≈ $-144.55 |
-25.18% |
| 2013-12-31 | GBX-949.00K ≈ $-115.47 |
-13.38% |
| 2012-12-31 | GBX-837.00K ≈ $-101.84 |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Faron Pharmaceuticals Oy's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 18996100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | GBX2.69 Million | % |
| Other Comprehensive Income | GBX184.97 Million | % |
| Total Equity | GBX-9.76 Million | 100.00% |
Faron Pharmaceuticals Oy Competitors by Market Cap
The table below lists competitors of Faron Pharmaceuticals Oy ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Chariot Oil & Gas Limited
LSE:CHAR
|
$575.39K |
|
PROMIS NEUROSCIENCES
F:23J0
|
$576.86K |
|
BEBO Health SA
PA:MLBBO
|
$579.76K |
|
KINGMAN MINERALS LTD.
F:47A
|
$580.13K |
|
Gyldendal A/S
CO:GYLD-B
|
$573.85K |
|
MEDICOX Co. Ltd
KQ:054180
|
$573.12K |
|
STV Group plc
LSE:STVG
|
$572.60K |
|
Ireka Corporation Bhd
KLSE:8834
|
$571.89K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Faron Pharmaceuticals Oy's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -15,161,000 to -9,762,000, a change of 5,399,000.
- Net loss of 25,920 reduced equity.
- New share issuances of 31,850,000 increased equity.
- Other comprehensive income increased equity by 184,813,643.
- Other factors decreased equity by 211,238,723.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX-25.92K | -0.27% |
| Share Issuances | GBX31.85 Million | +326.27% |
| Other Comprehensive Income | GBX184.81 Million | +1893.19% |
| Other Changes | GBX-211.24 Million | -2163.89% |
| Total Change | GBX- | % |
Book Value vs Market Value Analysis
This analysis compares Faron Pharmaceuticals Oy's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | GBX-0.03 | GBX41.50 | x |
| 2013-12-31 | GBX-0.03 | GBX41.50 | x |
| 2014-12-31 | GBX-0.04 | GBX41.50 | x |
| 2015-12-31 | GBX0.45 | GBX41.50 | x |
| 2016-12-31 | GBX0.38 | GBX41.50 | x |
| 2017-12-31 | GBX0.14 | GBX41.50 | x |
| 2018-12-31 | GBX0.01 | GBX41.50 | x |
| 2019-12-31 | GBX0.04 | GBX41.50 | x |
| 2020-12-31 | GBX-0.03 | GBX41.50 | x |
| 2021-12-31 | GBX0.05 | GBX41.50 | x |
| 2022-12-31 | GBX-0.17 | GBX41.50 | x |
| 2023-12-31 | GBX-0.19 | GBX41.50 | x |
| 2024-12-31 | GBX-0.11 | GBX41.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Faron Pharmaceuticals Oy utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-582.94%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | GBX-2.38 Million |
| 2013 | 0.00% | -754.00% | 0.09x | 0.00x | GBX-1.41 Million |
| 2014 | 0.00% | -150.55% | 0.42x | 0.00x | GBX-1.25 Million |
| 2015 | -55.36% | -1190.00% | 0.04x | 1.33x | GBX-7.31 Million |
| 2016 | -85.40% | -806.07% | 0.07x | 1.59x | GBX-10.38 Million |
| 2017 | -444.02% | -1408695.65% | 0.00x | 3.14x | GBX-21.53 Million |
| 2018 | -5443.36% | -105715.79% | 0.00x | 21.69x | GBX-20.12 Million |
| 2019 | -823.73% | 0.00% | 0.00x | 6.34x | GBX-13.42 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | GBX-16.76 Million |
| 2021 | -726.32% | 0.00% | 0.00x | 4.52x | GBX-21.49 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | GBX-27.58 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | GBX-29.43 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | GBX950.28K |
Industry Comparison
This section compares Faron Pharmaceuticals Oy's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $8,640,498
- Average return on equity (ROE) among peers: -270.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Faron Pharmaceuticals Oy (FARN) | GBX-16.25 Million | 0.00% | N/A | $575.13K |
| 4BASEBIO UK SOCIETAS (4BB) | $7.12 Million | -72.33% | 0.64x | $951.45K |
| Aptamer Group PLC (APTA) | $245.81K | -274.50% | 4.65x | $205.09K |
| Arecor Therapeutics PLC (AREC) | $5.35 Million | -191.36% | 0.63x | $303.20K |
| Avacta Group PLC (AVCT) | $29.89 Million | -21.30% | 0.06x | $3.99 Million |
| BSF Enterprise Plc (BSFA) | $3.58 Million | -25.96% | 0.13x | $27.33K |
| Bioventix (BVXP) | $11.01 Million | 51.43% | 0.08x | $1.10 Million |
| Cizzle Biotechnology Holdings PLC (CIZ) | $32.00K | -956.25% | 1.81x | $127.81K |
| Amur Minerals Corporation (CRTX) | $20.48 Million | -8.91% | 0.04x | $80.26K |
| Fusion Antibodies PLC (FAB) | $50.13K | -935.06% | 5.06x | $193.60K |
About Faron Pharmaceuticals Oy
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. Its lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-ass… Read more